PubMed · 1983 · 14 citations · 20 references
Life SciencesImmunologyPathologyAutoimmunityClinical ImmunologyImmunopathologyAntibody CharacterizationAntibody FunctionAutoantibodiesAutoimmune DiseasesComplement SystemSystemic Lupus ErythematosusActivationC4 Complement LevelsComplement Activation AssaysComplement Assay DevelopmentComplement In Autoimmune DiseaseComplement In Disease PathogenesisSystemic Lupus Erythematosus AssociationsSystemic Lupus Erythematosus Diagnostics
An enzyme linked immunosorbent assay was developed to quantitate antibodies to Sm (anti-Sm) and to measure complement activation by anti-Sm in vitro. Anti-Sm in plasma of patients with systemic lupus erythematosus (SLE) were bound to purified Sm bound to polyvinyl chloride microtitre plates and assayed for bound IgG or IgM using enzyme linked anti-gamma or anti-mu. The activation of C4 by anti-Sm was measured by adding diluted normal human serum (complement) to the wells and quantitating the amount of C4 bound to the well surface using (Fab')2 goat anti-C4 followed by enzyme linked rabbit anti-goat IgG. The plasmas of 12 of 36 patients with SLE contained anti-Sm and all 12 activated complement (complement activating anti-Sm). Twenty-eight plasmas containing anti-Sm from 12 patients with SLE were studied. Ten of the 12 patients had anti-Sm of the IgG class whereas two had anti-Sm of both IgG and IgM classes. The amount of C4 activating anti-Sm correlated significantly with the in vivo activation of C4 measured by rocket immunoelectrophoresis for C4d and C4, suggesting that complement activation by anti-Sm is important in vivo.
20